Direct Channel Opportunity Centaur maintains a direct sales capability alongside distributors, with approximately 1,000 direct accounts and 450 USDA approved laboratories. This presents a pathway to upsell diagnostic, pharmaceutical, or nutraceutical offerings directly to labs and veterinary labs that prefer or require direct purchasing.

Niche Diagnostic Focus The company leverages breakthrough diagnostic technologies, including equine EIA tests originally adapted from human healthcare. Targeting laboratories and clinics handling equine and companion animal diagnostics could yield opportunities to introduce innovative, patent-protected tests and related services.

Contract Manufacturing Potential With FDA and DEA certified facilities and a model that licenses patented technologies, Centaur could be a partner for contract development or manufacturing of diagnostics, pharmaceuticals, or nutraceuticals for animal health clients seeking reliable production capabilities.

Small Team, Niche Focus Operating with a compact team, Centaur may be agile in adopting scalable solutions such as distribution partnerships, white-label diagnostics, or channel programs. This supports rapid pilots with select distributors and labs to expand market reach.

Expansion into Production Animals While historically equine-focused, Centaur’s stated focus on companion and production animals indicates potential growth in diagnostics and therapeutics across broader animal health segments, suggesting cross-sell opportunities to existing distributor networks and USDA labs handling diverse species.